
HUTCHMED (China) Investor Relations Material
Latest events

Investor Update
HUTCHMED (China)
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from HUTCHMED (China) Limited
Access all reports
HUTCHMED Limited is a global biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company integrates innovative science and clinical expertise to develop a robust pipeline of therapies, leveraging its research and development capabilities in China and internationally. HUTCHMED markets its products in various regions and collaborates with global pharmaceutical partners for distribution and development. The company is headquartered in Hong Kong, China, and its shares are listed on the NASDAQ and the London Stock Exchange (LSE).
Key slides for HUTCHMED (China) Limited


H1 2024
HUTCHMED (China) Limited


H1 2024
HUTCHMED (China) Limited
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
HCM
Country
🇬🇧 United Kingdom